Leishmaniasis in humans: drug or vaccine therapy?

M Ghorbani, R Farhoudi - Drug design, development and therapy, 2017 - Taylor & Francis
Leishmania is an obligate intracellular pathogen that invades phagocytic host cells.
Approximately 30 different species of Phlebotomine sand flies can transmit this parasite …

Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

F Chappuis, S Sundar, A Hailu, H Ghalib… - Nature reviews …, 2007 - nature.com
Visceral leishmaniasis (VL) is a systemic protozoan disease that is transmitted by
phlebotomine sandflies. Poor and neglected populations in East Africa and the Indian sub …

Advances in leishmaniasis

HW Murray, JD Berman, CR Davies, NG Saravia - The Lancet, 2005 - thelancet.com
Governed by parasite and host factors and immunoinflammatory responses, the clinical
spectrum of leishmaniasis encompasses subclinical (inapparent), localised (skin lesions) …

Kinetoplastids: related protozoan pathogens, different diseases

K Stuart, R Brun, S Croft, A Fairlamb… - The Journal of …, 2008 - Am Soc Clin Investig
Kinetoplastids are a group of flagellated protozoans that include the species Trypanosoma
and Leishmania, which are human pathogens with devastating health and economic effects …

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda

PJ Guerin, P Olliaro, S Sundar, M Boelaert… - The Lancet infectious …, 2002 - thelancet.com
Visceral leishmaniasis is common in less developed countries, with an estimated 500 000
new cases each year. Because of the diversity of epidemiological situations, no single …

Vaccines for visceral leishmaniasis: A review

K Jain, NK Jain - Journal of immunological methods, 2015 - Elsevier
Visceral leishmaniasis, which is also known as Kala-Azar, is one of the most severely
neglected tropical diseases recognized by the World Health Organization (WHO). The threat …

Vaccines to prevent leishmaniasis

R Kumar, C Engwerda - Clinical & translational immunology, 2014 - Wiley Online Library
Leishmaniasis is a parasitic disease that encompasses a range of clinical manifestations
affecting people in tropical and subtropical regions of the world. Epidemiological and …

Leishmaniasis: new approaches to disease control

CR Davies, P Kaye, SL Croft, S Sundar - Bmj, 2003 - bmj.com
Leishmaniasis: new approaches to disease control | The BMJ Skip to main content Intended
for healthcare professionals Access provided by Google Indexer Subscribe My Account My …

From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection

G Volpedo, RH Huston, EA Holcomb… - Expert review of …, 2021 - Taylor & Francis
Introduction Leishmaniasis is a major public health problem and the second most lethal
parasitic disease in the world due to the lack of effective treatments and vaccines. Even …

Second-generation vaccines against leishmaniasis

RN Coler, SG Reed - Trends in parasitology, 2005 - cell.com
Several species of Leishmania cause human diseases that range from self-healing
cutaneous lesions to fatal visceral leishmaniasis, mucosal leishmaniasis and diffuse …